Drug intelligence / Profile preview

CC-02-1

Development stage: Preclinical
Lead developer: CompleCure
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**CC-02-1** is a preclinical **HER2-targeted antibody-drug conjugate** being developed by CompleCure for **extramammary Paget disease**. The program is intended to bind HER2-expressing tumor cells and deliver a covalently linked cytotoxic payload intracellularly, enabling targeted antitumor activity. CompleCure lists CC-02-1 as a preclinical HER2 ADC for Paget's disease of the skin. ([complecure.com](https://www.complecure.com/en))

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA

Beyond the preview

Go deeper on CC-02-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-02-1.

Explore the full profile